Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy

Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy Mizuki Yoshimoto, Shin-ichiro Yanagiya, Hiroki Takanari, Takeshi Honda, and 13 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6795517/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Although the prognosis of cardiac amyloidosis has improved with the development of therapies, the time required for disease typing remains a critical issue. We investigated the potential of Raman spectroscopy for the more rapid diagnosis and typing of cardiac amyloidosis. Heart biopsies were collected from patients with the AL (4) and ATTR (4) types of cardiac amyloidosis, and tissue sections were subjected to Raman microscopy. A principal component analysis (PCA) of spectral data was performed and receiver operating characteristic (ROC) curves were created to confirm the accuracy of discriminating between amyloid-deposition and non-deposition sites, and between AL and ATTR. The steep peak at 1680 cm -1 , reflecting the β-sheet structure, was useful for detecting the amyloid-deposition region. By restricting the spectral analysis to amyloid-deposition sites, AL and ATTR were discriminated by principal components with a characteristic broad peak at 1520–1540 cm -1 , which was also observed in the Raman spectrum of AL, but not ATTR. The area under ROC curve discriminating AL and ATTR was 0.78. PCA of the Raman spectra of cardiac biopsies has the potential not only to detect amyloid-deposition sites in tissue but also to rapidly discriminate between the AL and ATTR types of cardiac amyloidosis. Biological sciences/Biological techniques Health sciences/Cardiology Physical sciences/Nanoscience and technology Cardiac amyloidosis Rapid diagnosis Immunoglobulin light chains Transthyretin Raman spectroscopy Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Introduction Amyloidosis is the general term used for diseases in which amyloid proteins with an abnormal three-dimensional structure are deposited in tissues, causing organ damage and dysfunction. There are more than 40 known precursor proteins that produce amyloid proteins, and the types of amyloid proteins deposited in organs differ and cause specific symptoms. The pathophysiological condition of amyloid protein accumulation in the heart is called cardiac amyloidosis. Typical precursor proteins that give rise to cardiac amyloidosis are immunoglobulin light chains and transthyretin, termed the AL and ATTR types, respectively. Cardiac amyloidosis has a poor prognosis with many cases of sudden death due to pump failure and fatal arrhythmias, especially in AL, where the frequency of fatal complications is reported to be high 1 . In recent years, several new agents have been developed to improve the prognosis of the AL and ATTR types of cardiac amyloidosis. Daratumumab is a human IgG-κ monoclonal antibody that targets CD38, which is highly expressed on human plasma cells. Recent clinical studies showed that daratumumab combined with chemotherapy achieved better event-free survival and hematological responses in newly diagnosed systemic AL amyloidosis patients, including cardiac amyloidosis 2 – 4 . Tafamidis, developed as a pharmacological chaperone, improved the prognosis of patients with ATTR cardiac amyloidosis by stabilizing the tetrameric structure of transthyretin and inhibiting its tissue deposition 5 , 6 . In current clinical practice, when amyloidosis is suspected, several biopsy samples are taken from patients, and if amyloid deposition is detected, the disease type is identified via immunostaining and a genetic diagnosis, which is very time-consuming, taking several weeks to several months. In this context where effective treatments are being developed, a more rapid diagnosis to identify the type of cardiac amyloidosis is needed. Raman spectroscopy is a label-free optical measurement technique that assesses molecular structures by measuring the spectrum of scattered light induced by single-wavelength laser irradiation and detecting the wavenumber shift from irradiated light 7 . Each molecule has a unique “spectral fingerprint” depending on vibrating patterns, which may be identified by chemical bonds and three-dimensional structures. Raman spectroscopy has recently been used in analyses in biological and medical research 8 – 10 . It is a non-destructive technique that does not depend on the state of samples, which enables its application to live organs. Raman spectroscopy is useful for detecting tumors 11 – 13 , myocardial infarction 14 , skin inflammation 15 and amyloid-β protein in Alzheimer’s disease 16 – 18 . Raman spectroscopy is also increasingly used as a surgery-assisting tool 19 , 20 . In recent years, many attempts have been made to improve diagnostic accuracy by using artificial intelligence (AI) or machine learning to analyze spectra obtained by Raman spectroscopy 15 , 21 , 22 . However, living organs comprise a wide variety of molecules, each of which produces scattered light with multiple Raman shifts, and when these overlap, it becomes difficult to identify single molecules. On the other hand, in pathologies such as amyloidosis, a single substance aggregates densely in tissue and, thus, it is easier to detect. We previously examined clinical biopsy specimens from patients with amyloidosis and reported that optical mapping based on Raman spectra derived from the β-sheet structure, which is abundant in amyloid protein, detected amyloid-deposition sites 23 . Our findings demonstrated the potential of a Raman spectroscopic analysis to more rapidly diagnose amyloid deposition in tissues. However, it remains unclear whether it has the ability to detect differences in disease types. Therefore, with the aim of rapidly diagnosing the disease type of cardiac amyloidosis, we herein analyzed spectra in more detail to establish whether a Raman spectral analysis discriminates between the AL and ATTR types of cardiac amyloidosis. Results Patient background Table 1 shows the summarized data of patients enrolled in the present study. Between 2018 and 2024 we treated 4 AL and 4 ATTR cardiac amyloidosis patients. Although the small number of patients who participated during the current study period makes it difficult to examine the significance of differences, the followings were observed. 1) Patients with ATTR amyloidosis were slightly older than those with AL amyloidosis. 2) The NYHA functional classification, which represents the clinical severity of heart failure, was higher in AL amyloidosis than in ATTR amyloidosis, indicating that AL amyloidosis resulted in more severe heart failure. 3) The thicknesses of interventricular septum and left ventricular posterior wall in echocardiography, which indicate myocardial hypertrophy, were slightly wider in ATTR, suggesting that cardiac hypertrophy was more intense in ATTR cardiac amyloidosis. 4) The serum level of brain natriuretic peptide, a biomarker of heart failure, was slightly higher in AL amyloidosis, also suggesting that heart failure was more severe in the AL type of cardiac amyloidosis than in the ATTR type. Such patient background was well consistent with previous reports of sudden death in AL and ATTR types of cardiac amyloidosis 1 . Table 1 Patient data on AL and ATTR cardiac amyloidosis. AL ( n = 4) ATTR ( n = 4) Age 64.0 (49–74) 76.0 (65–88) Male (Female) 1 (3) 3 (1) Number of NYHA class III or IV 3 1 BNP [pg/mL] 1992.3 (65.5–5679.8) 231.4 (99.1–330.3) LVDd [mm] 43.0 (33–54) 48.0 (46–50) LVEF [%] 56.8 (48–66) 56.3 (45–62) %FS [%] 28.0 (18–49) 27.5 (23–38) IVST [mm] 12.1 (8.3–14.2) 12.7 (8.6–15.4) LVPWT [mm] 11.9 (7.8–14.9) 12.5 (8.8–14.9) LAD [mm] 45.0 (35–50) 46.8 (37–51) NYHA class: New York Heart Association functional classification, BNP: brain natriuretic peptide, LVDd: diastolic left ventricular diameter, LVEF: left ventricular ejection fraction, %FS: fractional shortening, IVST: thickness of the interventricular septum, LVPWT: thickness of the left ventricular posterior wall, LAD: left atrial diameter. Raman imaging and Raman spectra of AL and ATTR cardiac amyloidosis Representative transmitted light microscopy images (Fig. 1 A) and polarized light microscopy images (Fig. 1 B) of Congo-Red-stained specimens as well as transmitted light microscopic images of unstained specimens (Fig. 1 C), Raman images (Fig. 1 D) and Raman spectra (Fig. 1 E) obtained from adjacent unstained specimens are shown. Similar to our previous findings 23 , amyloid-deposition areas that stain red with Congo-Red and exhibited apple green birefringence in polarized light microscopy were shown in white in the Raman image, indicating that Raman intensity at 1680 cm − 1 was very strong. Additionally, the peak at 1680 cm − 1 , which was assigned to an amide I bond, was clearly visible at the amyloid deposition sites of AL and ATTR cardiac amyloidosis. This was consistent with our previous findings 23 . Detection of amyloid-deposition regions in heart tissue based on principal component analysis (PCA) of Raman spectra To assess differences more objectively in Raman spectra between normal and amyloid-deposition areas, we performed PCA of total Raman spectral data to create scatter plots of two different principal components (PCs). Figure 2 A shows a scatterplot based on PC1 and PC3. Although there was some overlap, plots of the amyloid deposition areas (closed dots) were more likely to be clustered in the dotted box, while those of normal tissue areas (open dots) were more likely to be dispersed around them. To confirm whether the results of PCA of Raman spectra discriminated between amyloid-deposition and non-deposition regions, we created a receiver operating characteristic (ROC) curve based on PC3 obtained by PCA. The area under the curve (AUC), sensitivity, and specificity were 0.78, 0.84, and 0.74, respectively. We also tested the ability to identify amyloid deposition sites based on Raman spectra separately for AL and ATTR cardiac amyloidosis. Figure S1 A is a scatter plot based on the results of PCA of Raman spectroscopy of AL cardiac amyloidosis. Although there was some overlap, the distribution of the plots of amyloid deposition area (orange dots) and normal area (open dots) appeared to differ. The ROC curve based on PCA results showed AUC of 0.69, sensitivity of 0.87, and specificity of 0.59 (Fig. S1 A). Figure S2 A is a scatterplot based on the results of PCA of Raman spectroscopy of ATTR cardiac amyloidosis. Although there was some overlap, the distribution of plots of the amyloid deposition area (green dots) and normal area (open dots) appeared to differ. The ROC curve based on PCA results showed that AUC, sensitivity, and specificity were 0.77, 0.75, and 0.88, respectively (Fig. S2 B). These results suggest the potential to detect amyloid-deposition sites with high accuracy based on the PCA of Raman spectroscopy. Discrimination of AL and ATTR cardiac amyloidosis based on principal component analysis of Raman spectra. We performed PCA using only data obtained from amyloid deposition regions in both AL and ATTR cardiac amyloidosis to investigate whether it is possible to distinguish between the AL and ATTR types. Figure 3 A shows a scatterplot of PC1 and PC6 based on the PCA of data limited to amyloid deposition areas. Although there was a slight overlap, AL (orange dots) and ATTR (green dots) were separated by positive and negative values of PC6, respectively. Figure 3 B shows the ROC curve generated to confirm whether AL and ATTR may be discriminated based on the results of the PCA of Raman spectra obtained at amyloidosis deposition areas. AUC, sensitivity, and specificity were 0.78, 0.80, and 0.71, respectively. In Fig. 4 , the average spectral waveforms of the amyloid deposition regions in AL and ATTR cardiac amyloidosis were compared side by side with the loading waveform of PC6 in the wavenumber range of 1250–1800 cm − 1 . A difference was observed between the Raman spectral intensities of AL and ATTR in the range of 1520–1540 cm − 1 (solid box). Multiple peak-fitting in the range of 1500–1550 cm − 1 revealed a typical peak at 1537 cm − 1 in the spectrum of AL, but not ATTR. The loading wave of PC6 obtained by the PCA of Raman spectra in amyloid-deposition regions shows an upward broad peak at 1537 cm − 1 (dotted box). The spectral difference in 1520–1540 cm − 1 was considered to contribute to the highly accurate discrimination of AL and ATTR based on PC6. We then investigated whether the difference in the Raman peak at 1537 cm − 1 in amyloid-deposition regions in AL and ATTR was due to variations in the amino acid content of their precursor proteins. Figure 5 shows the three-dimensional structure of amyloid fibrils consisting of immunoglobulin light chains (lambda type) with the IGLV1-44 mutation, which is one of the most common mutations observed in AL amyloidosis 24 , and wild-type transthyretin 25 . The amino acid sequences of both precursor proteins are shown in Figure S3, and the content of amino acids in both proteins are also summarized in Table S1 in supplementary data. According to previous studies 26 , 27 , among the 20 amino acids that make up the human body, those with peaks around the wavenumber of 1538 cm − 1 were glycine (1515 cm − 1 ), asparagine (1541 cm − 1 ), isoleucine (1547 cm − 1 ), leucine (1514 cm − 1 ), proline (1548 cm − 1 ), and tryptophan (1559 cm − 1 ). The total numbers of the six amino acids in the amyloid-forming portion of immunoglobulin light chains and transthyretin were 31 (34%) and 29 (26%), respectively. Their content differed by 8%. As shown in Fig. 5 , the content of six amino acids colored red differed and also appeared to be denser and in closer proximity in immunoglobulin light chains than in transthyretin. The different amino acid sequences of the precursor proteins may be responsible for the differences observed in Raman spectra in amyloid-deposition areas of the two disease types of cardiac amyloidosis. Discussion We successfully performed Raman spectroscopy on formalin-fixed paraffin-embedded sections of myocardial biopsy samples from patients with cardiac amyloidosis to detect sites of amyloid deposition in cardiac tissue. Furthermore, a detailed Raman spectral analysis using PCA revealed the potential to distinguish between the two most common forms of amyloid deposition in the heart, AL and ATTR. Since Raman spectroscopy is an optical analysis that is non-destructive and does not require special sample preparation, it has been considerd to be useful for biological applications, especially as an aid in medical diagnosis, and much research has been conducted. However, spectra derived from living organs contain a large amount of foreign information and are very difficult to analyze. Recent developments in AI and machine learning have provided one solution to this problem 15 , 21 , 22 . PCA is a statistical analysis method that aggregates data with many variables to create PCs to reduce the dimensionality of the data and facilitate comparison between data, and is a method frequently used in analysis of Raman spectral data as a type of unsupervised machine learning. In this study, we verified whether it is possible to detect amyloid deposition or discriminate between AL and ATTR based on the PCs obtained by PCA, and showed that the ROC curve had good diagnostic ability with an AUC of approximately 0.8. In the future, it is expected that more clinical data will be collected and supervised machine learning will be applied to enable even higher accuracy in diagnosis. The problem still remains that diagnosis by AI and machine learning obscures the basis for the diagnosis, and explainable AI (XAI) would be one solution for this problem. Recently, XAI has been applied especially in the field of diagnostic imaging, and there is an increasing demand for XAI to show the basis of diagnosis 28 , 29 . However, XAI is not yet easy to introduce due to the complexity of the program, development costs, and other reasons. In such situation, it is also very important to add pathological or material science considerations to the differences in analysis of Raman spectra in order to obtain diagnostic certainty on a rational basis. We carefully examined the PCs obtained by PCA and the raw spectral data and found that the peak at 1680 cm − 1 and 1537 cm − 1 may be useful for detecting amyloid accumulation and discriminating between AL and ATTR, respectively. Furthermore, we tried to obtain theoretical support for the diagnosis based on these peaks by considering what molecular structure each peak is derived from. We previously reported that the Raman peak assigned to the Amid-I bond near 1680 cm − 1 was useful for detecting amyloid deposition in the tissues of various organs, including the heart, in patients with AL amyloidosis 23 . Since a Raman spectroscopic analysis of immunoglobulins revealed a peak for the Amid-I bond 30 , 31 , we considered the peak for the Amid-I bond to be specific to AL amyloidosis. However, in the present study, the Raman peak at 1680 cm − 1 was still visible in amyloid-deposition regions, even in cardiac biopsy samples from ATTR amyloidosis patients. Therefore, we concluded that the 1680 cm − 1 peak was derived from the β-sheet structure of amyloid protein. Amyloid protein, which is deposited in tissues in amyloidosis, is a general term for a single protein that transforms into a β-sheet structure. The precursor proteins and peptides of amyloid proteins differ depending on the disease, with immunoglobulin light chains aggregating in AL and transthyretin aggregating in ATTR. Even though the precursor proteins differ, the β-sheet structure that is common to amyloid protein aggregates in a narrow region 24 , 25 , and the Raman peak at 1680 cm − 1 assigned to the β-sheet structure of the Amid-I bond is considered to be useful for detecting amyloid deposition areas with high sensitivity 32 , 33 . In the present study, we analyzed the Raman spectra of amyloid deposition sites in detail and showed the possibility that differences in precursor proteins were reflected in Raman spectra. In a comparison of Raman spectra restricted to the amyloid deposition area, we found an apparent difference in Raman intensity between the AL and ATTR types of cardiac amyloidosis at the 1520–1540 cm − 1 wavenumber region. A detailed analysis by peak fitting also revealed a characteristic peak at 1537 cm − 1 in the AL type of cardiac amyloidosis, but not in the ATTR type. This difference in Raman spectra at 1537 cm − 1 may have been due to different amino acid sequences in the precursor proteins of AL and ATTR and, thus, we compared the amino acid sequences of the amyloid fibril-forming parts of immunoglobulin light chains and transthyretin. We found that the content of amino acids, which have a Raman peak near 1537 cm − 1 26, 27 , was nearly 10% higher in immunoglobulin light chains than in transthyretin. Since the intensity of the Raman spectra of each amino acid must also be considered and spectra may change due to peptide binding, it is still difficult to draw conclusions based on amino acid contents alone. Although studies comparing the Raman spectra of amino acids with those of peptides and proteins have been conducted since the development of Raman spectroscopy, differences in amino acid sequences and complex three-dimensional structures have made it difficult to predict changes in Raman spectra 34 . Attempts have been made to diagnose diseases using amino acids and peptides with characteristic spectra, such as aromatic amino acids and protonated phosphate groups, as indicators, but these have not been put to practical use 35 , 36 . It has been reported that by combining machine learning models, which have been remarkably developed in recent years, with classical force-field molecular dynamics, it has become possible to construct a model that predicts the Raman spectra of peptides from the Raman spectra of amino acids 37 – 39 . If more data are accumulated and such models are established in the future, it may be possible to predict variations in Raman spectra due to differences in precursor proteins in advance, and also to construct a model that discriminates disease types based on these predicted Raman spectra. The prognosis of patients with systemic amyloidosis is negatively impacted by cardiac amyloidosis, which causes amyloid deposition in the heart. Even in non-fatal cases, cardiac amyloidosis is associated with repeated heart attacks and significantly impairs the quality of life of patients. Although the prognosis of cardiac amyloidosis has improved in recent years with the development of new therapies 2 – 6 , a prompt diagnosis is essential for the initiation of treatment as soon as possible in order to maximize therapeutic effects. Moreover, since treatment methods differ between AL and ATTR amyloidosis, it is important to rapidly diagnose not only the presence or absence of amyloid deposition, but also the disease type. Until now, research on the diagnosis of amyloidosis by Raman spectroscopy has mainly focused on the detection of amyloid protein. Kim et al. reported that Raman spectroscopy could not only identify the site of amyloid deposition in renal amyloidosis but also discriminate between amyloid A (AA) and AL types of amyloidosis 40 . This was one of the few studies to demonstrate the applicability of Raman spectroscopy to the classification of disease types in amyloidosis. To the best of our knowledge, the present study is the first to classify of the disease types of cardiac amyloidosis using Raman spectroscopy and demonstrate its potential. In the future, if it becomes possible to detect amyloid deposition based on the peak derived from the Amid-I bond at 1680 cm − 1 and further classify the disease type based on the peak around 1537 cm − 1 using a detailed spectral analysis of the same region, the diagnosis of cardiac amyloidosis may be expedited. Since Raman spectroscopy may analyze unstained specimens, a rapid diagnosis may be possible after a biopsy sample is taken, which will enable the early initiation of treatment. There were several limitations that need to be addressed. The number of patients included was very small, 4 each for AL and ATTR, and it remains unclear whether a similar spectrum useful for diagnosis could be obtained when the patient number of cases increases. Another form of systemic amyloidosis that may be complicated by cardiac amyloidosis is AA amyloidosis due to chronic inflammation. AA amyloidosis was not involved in the present study. Furthermore, there are multiple forms of AL amyloidosis, such as the lambda and kappa types of immunoglobulin light chains, and ATTR amyloidosis, including the hereditary and wild types. Although it is necessary to diagnose these types in order to develop a precise treatment strategy for each patient, the number of cases in this study was small and we have not yet reached that level of classification. Further spectral analyses and the accumulation of more cases subjected to a Raman spectroscopic analysis are necessary in the future. Materials and Methods Collection of clinical biopsy samples All clinical studies were approved by the Institutional Review Board of Tokushima University (approval number: 3507-3). All methods were performed in accordance with the guidelines and regulations of Tokushima University, which was created on the basis of Declaration of Helsinki. Written informed consent was obtained from patients for the collection of biopsy samples for diagnosis and the use of some specimens for research purposes. The background data of patients enrolled in the present study are summarized in Table 1. Cardiac biopsy samples were fixed in formalin and embedded in paraffin, and two or more serial sections (thickness of 3 µm) were prepared using a microtome. One of the serial sections was stained with Congo Red for polarized light microscopy and the adjacent sections were left unstained for Raman spectroscopy. Raman microscopy and image construction Prior to Raman microscopy, Congo Red stained specimens were observed by polarized light microscopy (OPTIPHOT2-POL, Nikon Co.) to identify the area with apple green birefringence, which was presumed to be the amyloid deposition site. Based on the findings of polarized light microscopy, we identified the location for Raman spectroscopy as the region of interest. Consecutive unstained specimens were observed by Raman spectroscopy (Raman11, Nanophoton Corporation, Osaka, Japan) as previously described 23 . The laser (central wavelength 532 nm, power 10–12 mW) was illuminated through an objective lens (LUCPLAN, x20, N.A. 0.45, Olympus Co., Tokyo, Japan) and sample observations were simultaneously performed through the same objective lens. Measurements were conducted in the x-y line scan mode. Briefly, the laser was expanded in the x-axis direction to illuminate the sample in a linear manner (exposure time 600 s), and the resulting spectral data were simultaneously acquired by 400 CCD array and scanned repeatedly in the y-axis direction 70–80 times. The diffraction grating and central wavenumber were 1200 lines/mm and 1850 cm − 1 , respectively. The measurement range and wavenumber resolution were approximately 1350–2350 cm − 1 and 0.9 cm − 1 , respectively. A final spatial resolution of 1 µm was achieved, and data including Raman spectra were acquired for each pixel. A Raman image was constructed based on spectral information of each pixel. The ratio of Raman scattering intensities in the wavenumber range of 1665–1680 cm − 1 to that in the wavenumber range of 1580–1600 cm − 1 was calculated, and the image was displayed with a pseudo-color gradient of black, magenta, cyan, and white from the lowest to highest ratio. PCA and creation of ROC curves The Raman spectra of normal and amyloid-deposition areas were extracted, and numerical data were subjected to PCA. A two-dimensional scatter plot analysis was performed based on extracted PCs. ROC curves were constructed to evaluate sensitivity and specificity for predicting amyloid deposition or the discrimination of disease types based on PCA. PCA of the spectral data and a ROC curve analysis were performed using Python ver.3.10.9 41 . A more detailed spectral analysis within the wavenumber range of interest was conducted using multiple peak-fitting method by Igor Pro ver.9.0.5.1 (WaveMetrics) 23 . Amino acid sequence analysis To investigate whether differences in the amino acid sequences of precursor proteins represent a difference in Raman spectra, we constructed the 3-dimensional structures of amyloid proteins of immunoglobulin light chains and transthyretin based on previous studies 24 , 25 , and colored several target amino acids in red using UCSF Chimera software 42 . Declarations Conflict of interest The authors declare that there is no conflict of interest. Funding sources This work was supported by the JSPS KAKENHI (grant number JP19H04443 [H.T.], JP20K08712 [H.M.], and JP22K04713 [S.Y.]), Health Laubour Science Research Grant (grant number 23FC1035 [H.M.]), Japanese Society of Hematology Research Grants (20289 and 24155), and Japan Leukaemia Research Fund [H.M.]. Author Contribution M.Y.: Investigation, formal analysis, software programming, writing-original draft. S.Y.: Conceptualization, investigation, software programming, formal analysis, writing-review & editing draft, funding. H.T.: Conceptualization, investigation, formal analysis, writing-review & editing draft, funding. T.H.: Investigation, formal analysis. Y.M.: Collection of clinical samples & data, review & editing the draft. R.S.: Collection of clinical samples & data, review & editing the draft. M.O.: Collection of clinical samples & data, review & editing the draft. K.S.: Collection of clinical samples & data, review & editing the draft. T.H.: Collection of clinical samples & data, review & editing the draft. S.F.: Collection of clinical samples & data, review & editing the draft. S.N.: Collection of clinical samples & data. Y.B.: Review & editing the draft. K.T.: Preparation of specimens, review & editing the draft. I.E.: Review & editing the draft. M.A.: Review & editing the draft. K.M.: Review & editing the draft. H.M.: Conceptualization, supervision, collection of clinical samples & data, investigation, formal analysis, writing-review & editing draft, funding. Acknowledgement The authors thank Prof. Takaaki Yano (Institute of Post-LED Photonics, Tokushima University, Tokushima, Japan) for all his help with instrumentation. The authors also thank Nanophoton, a Bruker Company, for their support in data acquisition. The authors appreciate Yuka Kanno (Division of Pathology, Tokushima University Hospital, Tokushima, Japan) for her technical assistance. Molecular graphics and analyses were performed with UCSF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311. We would like to thank Medical English Service for their assistance with English language editing. Data Availability All data supporting the findings of this study are available within this draft manuscript. References de Frutos, F. et al. Incidence and predictors of sudden death in patients with cardiac amyloidosis. Amyloid 31 , 334–338. 10.1080/13506129.2024.2414295 (2024). Kastritis, E. et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N. Engl. J. Med. 385 , 46–58. 10.1056/NEJMoa2028631 (2021). Oubari, S. et al. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica 109 , 220–230. 10.3324/haematol.2023.283325 (2024). Zanwar, S. et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 38 , 1423–1426. 10.1038/s41375-024-02243-5 (2024). Maurer, M. S. et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N. Engl. J. Med. 379 , 1007–1016. 10.1056/NEJMoa1805689 (2018). aus dem Siepen, F. et al. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval. Amyloid 31, 226–231, (2024). 10.1080/13506129.2024.2376202 Raman, C. V. & Krishnan, K. S. The Negative Absorption of Radiation. Nature 122 , 12–13. 10.1038/122012b0 (1928). Butler, H. J. et al. Using Raman spectroscopy to characterize biological materials. Nat. Protoc. 11 , 664–687. 10.1038/nprot.2016.036 (2016). Durrant, B., Trappett, M., Shipp, D. & Notingher, I. Recent developments in spontaneous Raman imaging of living biological cells. Curr. Opin. Chem. Biol. 51 , 138–145. 10.1016/j.cbpa.2019.06.004 (2019). Minamikawa, T. et al. Molecular imaging analysis of microvesicular and macrovesicular lipid droplets in non-alcoholic fatty liver disease by Raman microscopy. Sci. Rep. 10 , 18548. 10.1038/s41598-020-75604-6 (2020). Kong, K. et al. Diagnosis of tumors during tissue-conserving surgery with integrated autofluorescence and Raman scattering microscopy. Proc. Natl. Acad. Sci. U.S.A. 110 , 15189–15194. 10.1073/pnas.1311289110 (2013). Song, D. et al. Raman spectroscopy combined with multivariate analysis to study the biochemical mechanism of lung cancer microwave ablation. Biomed. Opt. Express . 11 , 1061–1072. 10.1364/BOE.383869 (2020). Ember, K. et al. In situ brain tumor detection using a Raman spectroscopy system—results of a multicenter study. Sci. Rep. 14 , 13309. 10.1038/s41598-024-62543-9 (2024). Yamamoto, T. et al. Label-free Evaluation of Myocardial Infarct in Surgically Excised Ventricular Myocardium by Raman Spectroscopy. Sci. Rep. 8 , 14671. 10.1038/s41598-018-33025-6 (2018). Kanemura, Y. et al. Assessment of skin inflammation using near-infrared Raman spectroscopy combined with artificial intelligence analysis in an animal model. Analyst 147 , 2843–2850. 10.1039/d2an00193d (2022). Popova, L. A., Kodali, R., Wetzel, R. & Lednev, I. K. Structural variations in the cross-beta core of amyloid beta fibrils revealed by deep UV resonance Raman spectroscopy. J. Am. Chem. Soc. 132 , 6324–6328. 10.1021/ja909074j (2010). Shashilov, V. et al. Dissecting structure of prion amyloid fibrils by hydrogen-deuterium exchange ultraviolet Raman spectroscopy. J. Phys. Chem. B . 116 , 7926–7930. 10.1021/jp2122455 (2012). Lochocki, B. et al. Multimodal, label-free fluorescence and Raman imaging of amyloid deposits in snap-frozen Alzheimer’s disease human brain tissue. Commun. Biology . 4 , 474. 10.1038/s42003-021-01981-x (2021). Hanna, K. et al. Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects. Br. J. Cancer . 126 , 1125–1139. 10.1038/s41416-021-01659-5 (2022). Zhang, Y. et al. Raman spectroscopy: A prospective intraoperative visualization technique for gliomas. Front. Oncol. 12 , 1086643. 10.3389/fonc.2022.1086643 (2022). Zhu, G. et al. Rapid diagnosis of membranous nephropathy based on kidney tissue Raman spectroscopy and deep learning. Sci. Rep. 15 , 13038. 10.1038/s41598-025-97351-2 (2025). Lazzini, G. et al. Raman spectroscopy based diagnosis of pancreatic ductal adenocarcinoma. Sci. Rep. 15 , 13240. 10.1038/s41598-025-98122-9 (2025). Yanagiya, S. et al. Raman microspectroscopy for label-free diagnosis of amyloid light-chain amyloidosis in various organs. J. Raman Spectrosc. 55 , 753–760. https://doi.org/10.1002/jrs.6665 (2024). Radamaker, L. et al. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat. Commun. 10 , 1103. 10.1038/s41467-019-09032-0 (2019). Schmidt, M. et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat. Commun. 10 , 5008. 10.1038/s41467-019-13038-z (2019). Zhu, G., Zhu, X., Fan, Q. & Wan, X. Raman spectra of amino acids and their aqueous solutions. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 78 , 1187–1195. https://doi.org/10.1016/j.saa.2010.12.079 (2011). Wen, C. I., Yu, C. N., Thirumalaivasan, N. & Hiramatsu, H. 532-nm-excited hyper-Raman spectroscopy of amino acids. J. Raman Spectrosc. 52 , 641–654. https://doi.org/10.1002/jrs.6039 (2021). van der Velden, B. H. M., Kuijf, H. J., Gilhuijs, K. G. A. & Viergever, M. A. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med. Image Anal. 79 , 102470. 10.1016/j.media.2022.102470 (2022). Salih, A. et al. Explainable Artificial Intelligence and Cardiac Imaging: Toward More Interpretable Models. Circ. Cardiovasc. Imaging . 16 , e014519. 10.1161/circimaging.122.014519 (2023). Ota, C., Noguchi, S., Nagatoishi, S. & Tsumoto, K. Assessment of the Protein-Protein Interactions in a Highly Concentrated Antibody Solution by Using Raman Spectroscopy. Pharm. Res. 33 , 956–969. 10.1007/s11095-015-1842-8 (2016). Ettah, I. & Ashton, L. Engaging with Raman Spectroscopy to Investigate Antibody Aggregation. Antibodies (Basel) . 7 10.3390/antib7030024 (2018). Pelton, J. T. & McLean, L. R. Spectroscopic methods for analysis of protein secondary structure. Anal. Biochem. 277 , 167–176. 10.1006/abio.1999.4320 (2000). Kurouski, D., Van Duyne, R. P. & Lednev, I. K. Exploring the structure and formation mechanism of amyloid fibrils by Raman spectroscopy: a review. Analyst 140 , 4967–4980. 10.1039/c5an00342c (2015). Garfinkel, D. Raman Spectra of Amino Acids and Related Compounds. XII. Various Amino Acids Derived from Proteins and Creatine1,2. J. Am. Chem. Soc. 80 , 3827–3831. 10.1021/ja01548a005 (1958). Xie, Y., Jiang, Y. & Ben-Amotz, D. Detection of amino acid and peptide phosphate protonation using Raman spectroscopy. Anal. Biochem. 343 , 223–230. 10.1016/j.ab.2005.05.038 (2005). Contorno, S., Darienzo, R. E. & Tannenbaum, R. Evaluation of aromatic amino acids as potential biomarkers in breast cancer by Raman spectroscopy analysis. Sci. Rep. 11 , 1698. 10.1038/s41598-021-81296-3 (2021). Paidi, S. K. et al. Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy. Cancer Res. 81 , 5745–5755. 10.1158/0008-5472.Can-21-1438 (2021). He, C. et al. Accurate Tumor Subtype Detection with Raman Spectroscopy via Variational Autoencoder and Machine Learning. ACS Omega . 7 , 10458–10468. 10.1021/acsomega.1c07263 (2022). Berger, E., Niemelä, J., Lampela, O., Juffer, A. H. & Komsa, H. P. Raman Spectra of Amino Acids and Peptides from Machine Learning Polarizabilities. J. Chem. Inf. Model. 64 , 4601–4612. 10.1021/acs.jcim.4c00077 (2024). Kim, J. H., Zhang, C., Sperati, C. J., Bagnasco, S. M. & Barman, I. Non-Perturbative Identification and Subtyping of Amyloidosis in Human Kidney Tissue with Raman Spectroscopy and Machine Learning. Biosens. (Basel) . 13. 10.3390/bios13040466 (2023). Python 3 Reference ManualCreateSpace, Scotts Valley, CA, (2009). Pettersen, E. F. et al. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25 , 1605–1612. 10.1002/jcc.20084 (2004). Additional Declarations No competing interests reported. Supplementary Files SciRepRamanSupple20250601.docx SciRepRamanFiguresSupple20250601.pdf Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6795517","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":473292618,"identity":"5be61b09-23c9-4782-ad65-6853bf84f0fb","order_by":0,"name":"Mizuki Yoshimoto","email":"","orcid":"","institution":"Faculty of Science and Technology, Tokushima University","correspondingAuthor":false,"prefix":"","firstName":"Mizuki","middleName":"","lastName":"Yoshimoto","suffix":""},{"id":473292619,"identity":"8a7801ea-9827-4330-a0d0-894b35c1a7e9","order_by":1,"name":"Shin-ichiro Yanagiya","email":"","orcid":"","institution":"Department of Next Generation Photonics, Institute of Post-LED Photonics","correspondingAuthor":false,"prefix":"","firstName":"Shin-ichiro","middleName":"","lastName":"Yanagiya","suffix":""},{"id":473292620,"identity":"f4a21649-e85f-4c94-8576-ee25e75e1165","order_by":2,"name":"Hiroki Takanari","email":"","orcid":"","institution":"Department of Legal Medicine, Nihon University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Hiroki","middleName":"","lastName":"Takanari","suffix":""},{"id":473292621,"identity":"aa5563e1-bc15-455c-8677-40903a923bd5","order_by":3,"name":"Takeshi Honda","email":"","orcid":"","institution":"Graduate School of Technology, Industrial and Social Sciences, Tokushima University","correspondingAuthor":false,"prefix":"","firstName":"Takeshi","middleName":"","lastName":"Honda","suffix":""},{"id":473292622,"identity":"d1d2fca7-0d00-40c2-841b-08e6b3f59706","order_by":4,"name":"Yusaku Maeda","email":"","orcid":"","institution":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Yusaku","middleName":"","lastName":"Maeda","suffix":""},{"id":473292623,"identity":"f86cd134-299a-4d33-bd05-71132ddeabc3","order_by":5,"name":"Ryohei Sumitani","email":"","orcid":"","institution":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Ryohei","middleName":"","lastName":"Sumitani","suffix":""},{"id":473292624,"identity":"86f13b47-a363-4823-9a59-4f60fdb8b8ea","order_by":6,"name":"Masahiro Oura","email":"","orcid":"","institution":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Masahiro","middleName":"","lastName":"Oura","suffix":""},{"id":473292625,"identity":"336c3878-5325-4429-923e-020dbb73ceeb","order_by":7,"name":"Kimiko Sogabe","email":"","orcid":"","institution":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Kimiko","middleName":"","lastName":"Sogabe","suffix":""},{"id":473292626,"identity":"98d07447-31bd-48b3-9b48-38dba02ee683","order_by":8,"name":"Takeshi Harada","email":"","orcid":"","institution":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Takeshi","middleName":"","lastName":"Harada","suffix":""},{"id":473292627,"identity":"caceeee9-08b1-4202-9778-d918d143ff42","order_by":9,"name":"Shiro Fujii","email":"","orcid":"","institution":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Shiro","middleName":"","lastName":"Fujii","suffix":""},{"id":473292628,"identity":"a70b4714-009a-449a-990a-989bbc06d0b8","order_by":10,"name":"Shingen Nakamura","email":"","orcid":"","institution":"Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Shingen","middleName":"","lastName":"Nakamura","suffix":""},{"id":473292629,"identity":"e921618e-e3cc-4797-8828-76887ea37c46","order_by":11,"name":"Yoshimi Bando","email":"","orcid":"","institution":"Division of Pathology, Tokushima University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yoshimi","middleName":"","lastName":"Bando","suffix":""},{"id":473292630,"identity":"9e2a62d0-ab41-486b-864a-c52bad66fca9","order_by":12,"name":"Koichi Tsuneyama","email":"","orcid":"","institution":"Department of Pathology and Laboratory Medicine, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Koichi","middleName":"","lastName":"Tsuneyama","suffix":""},{"id":473292631,"identity":"767bc5a2-e9d7-4bad-91ba-1d3f62c55746","order_by":13,"name":"Itsuro Endo","email":"","orcid":"","institution":"Department of Bioregulatory Sciences, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Itsuro","middleName":"","lastName":"Endo","suffix":""},{"id":473292632,"identity":"63e26950-9c4f-4ef8-a68b-9aa209e520c0","order_by":14,"name":"Masahiro Abe","email":"","orcid":"","institution":"Department of Hematology, Kawashima Hospital","correspondingAuthor":false,"prefix":"","firstName":"Masahiro","middleName":"","lastName":"Abe","suffix":""},{"id":473292633,"identity":"f98a138e-86e2-432f-aedd-93c2d19b3b9e","order_by":15,"name":"Ken-ichi Matsuoka","email":"","orcid":"","institution":"Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Ken-ichi","middleName":"","lastName":"Matsuoka","suffix":""},{"id":473292634,"identity":"65b3817b-1769-4fb7-9d44-a089ee829aab","order_by":16,"name":"Hirokazu Miki","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABBElEQVRIie3QMUvDQBTA8XcEzuWVridI/ASFhIPDqX6VCweuFlwdCoV06xxQv4MgOB88uEnI2kG0k5ODIHQK4ksFpya1W5H7TxeSH+9dAGKxQyyRQJABDPnIjx5/34jpDnJc/pmA3HwKWfghu/cazWVBk8lLql9npLF5PhnNvVRwPYbkZvsYQ9JTlV1pE6Rzg/INzZNlEhyI2+0jDR1NCTNbPAbUNOCz8ZdrBdKDqGw/eSiZYMOkXvGUrz7Ci7XkXqJ2KJkseTFR9hLbEq3ChcvvypaskrNi4bDzLnXQn9jYdDgjUu8NnZvaiuXHepzmHX+sI14J82ofselU7U1isVjsf/YN2WNbP6fY0pAAAAAASUVORK5CYII=","orcid":"","institution":"Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital","correspondingAuthor":true,"prefix":"","firstName":"Hirokazu","middleName":"","lastName":"Miki","suffix":""}],"badges":[],"createdAt":"2025-06-01 12:08:11","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6795517/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6795517/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":85346226,"identity":"384ef4da-61a4-4e4e-ab20-1e45bbaa7f92","added_by":"auto","created_at":"2025-06-25 02:08:42","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1797375,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eRepresentative histological findings and spectral data of AL (left) and ATTR (right) cardiac biopsy samples. A: \u003c/strong\u003e\u003c/em\u003eTransmitted light microscopy images of Congo Red stained specimens. \u003cem\u003e\u003cstrong\u003eB: \u003c/strong\u003e\u003c/em\u003ePolarized light microscopy images of Congo Red stained specimens. \u003cem\u003e\u003cstrong\u003eC:\u003c/strong\u003e\u003c/em\u003e Transmitted light microscopy images of adjacent unstained specimens. Yellow boxes indicate the area where Raman spectra were acquired and Raman images were created.\u003cem\u003e\u003cstrong\u003e D:\u003c/strong\u003e\u003c/em\u003e Raman images created from Raman spectra obtained from the yellow-framed region of unstained specimens in panel \u003cem\u003eC\u003c/em\u003e. The ratio of the Raman scattering intensities in the wavenumber range of 1665–1680 cm\u003csup\u003e-1\u003c/sup\u003e to that in the wavenumber range of 1580–1600 cm\u003csup\u003e-1\u003c/sup\u003e was calculated, and the image was displayed with a pseudo-color gradient of black, magenta, cyan, and white from the lowest to highest ratio. \u003cem\u003e\u003cstrong\u003eE:\u003c/strong\u003e\u003c/em\u003e Raman spectra recorded in the white (amyloid-deposition area), cyan (non-deposition area), and magenta (background) pixels of the Raman image in panel \u003cem\u003eD\u003c/em\u003e are shown from the top to bottom.\u003c/p\u003e\n\u003cp\u003eAL, amyloid light-chain; ATTR, amyloidosis of transthyretin\u003c/p\u003e","description":"","filename":"SciRepRamanFigures202506011.png","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/0bc3dcdf1b10e909e6f08c02.png"},{"id":85346222,"identity":"c9994d52-acda-45c0-b59f-2ffb79fcc884","added_by":"auto","created_at":"2025-06-25 02:08:41","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":105781,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eDiscrimination between amyloid-deposition and non-deposition regions based on PCA. A:\u003c/strong\u003e\u003c/em\u003e Scatter plots created by PC1 and PC3 obtained by PCA of the Raman spectra of amyloid-deposition (closed circles) and non-deposition (open circles) regions. The dotted box indicates the area where data from amyloid-deposition regions predominantly accumulated. \u003cem\u003e\u003cstrong\u003eB:\u003c/strong\u003e\u003c/em\u003e ROC curve for the detection of amyloid-deposition regions by PC1 and PC3 obtained by PCA of the Raman spectra of amyloid-deposition and non-deposition regions.\u003c/p\u003e\n\u003cp\u003ePCA, principal component analysis; PC principal component; ROC curve, receiver operating characteristic curve\u003c/p\u003e","description":"","filename":"SciRepRamanFigures202506012.png","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/454beb73958f1e8a98e9ddd1.png"},{"id":85346214,"identity":"a660dc67-9506-4159-9359-e3d4ebe47453","added_by":"auto","created_at":"2025-06-25 02:08:38","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":104753,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eDiscrimination between AL and ATTR cardiac amyloidosis based on PCA. A:\u003c/strong\u003e\u003c/em\u003e Scatter plots created by PC1 and PC6 obtained by performing PCA of the Raman spectra of amyloid-deposition regions in AL (orange circles) and ATTR (green circles) specimens. \u003cem\u003e\u003cstrong\u003eB:\u003c/strong\u003e\u003c/em\u003e ROC curve for the detection of AL by PC6 obtained by PCA of the Raman spectra of AL and ATTR samples.\u003c/p\u003e\n\u003cp\u003eAL, amyloid light-chain; ATTR, amyloidosis of transthyretin; PCA, principal component analysis; PC principal component; ROC curve, receiver operating characteristic curve\u003c/p\u003e","description":"","filename":"SciRepRamanFigures202506013.png","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/8c3fe17b742fd9a2b9d82013.png"},{"id":85346225,"identity":"2a70b910-63f6-47d3-9099-0e8e93b65166","added_by":"auto","created_at":"2025-06-25 02:08:42","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":52536,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eDetailed comparison of Raman spectra obtained from AL and ATTR cardiac amyloidosis samples. \u003c/strong\u003e\u003c/em\u003eThe averaged waveforms of Raman spectra from AL (orange line) and ATTR (green line) cardiac amyloidosis samples were compared side-by-side with the loading waveform of PC6 obtained by PCA of the Raman spectra of amyloid-deposition regions in AL and ATTR. The solid box shows an apparent difference in Raman intensity between AL and ATTR. An upward broad wave was observed in the loading waveform of PC6 in the same wavenumber region (dotted box).\u003c/p\u003e\n\u003cp\u003eAL, amyloid light-chain; ATTR, amyloidosis of transthyretin; PC principal component; PCA, principal component analysis\u003c/p\u003e","description":"","filename":"SciRepRamanFigures202506014.png","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/63d13067f25cd638e3591277.png"},{"id":85346220,"identity":"b87fb606-3b43-4107-9b0f-595bcd476186","added_by":"auto","created_at":"2025-06-25 02:08:40","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":652916,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eThree-dimensional structures of amyloid proteins comprising immunoglobulin (A) and transthyretin (B). \u003c/strong\u003e\u003c/em\u003eThe amino acid sequence in the amyloid-forming region of each protein is based on previous studies\u003csup\u003e24,25\u003c/sup\u003e. Amino acids with Raman spectra around 1537 cm\u003csup\u003e-1\u003c/sup\u003e are colored in red\u003csup\u003e26,27\u003c/sup\u003e.\u003c/p\u003e","description":"","filename":"SciRepRamanFigures202506015.png","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/d759c12a71b2d803288bde51.png"},{"id":85348474,"identity":"c25dfcb0-d434-42c3-b9ab-acfb328737bb","added_by":"auto","created_at":"2025-06-25 02:24:40","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3986824,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/14c3cb0e-aa04-4d79-a4ad-3389ae944ccc.pdf"},{"id":85346221,"identity":"bc9ab62b-5457-4e4b-b135-71f672866769","added_by":"auto","created_at":"2025-06-25 02:08:41","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":39110,"visible":true,"origin":"","legend":"","description":"","filename":"SciRepRamanSupple20250601.docx","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/4ad983e1186c476332f3559f.docx"},{"id":85346197,"identity":"bd8a1b3e-02ed-4305-84bb-c7a67a7ac3c0","added_by":"auto","created_at":"2025-06-25 02:08:37","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":501197,"visible":true,"origin":"","legend":"","description":"","filename":"SciRepRamanFiguresSupple20250601.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6795517/v1/feec6f82bb215fca18aa843a.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAmyloidosis is the general term used for diseases in which amyloid proteins with an abnormal three-dimensional structure are deposited in tissues, causing organ damage and dysfunction. There are more than 40 known precursor proteins that produce amyloid proteins, and the types of amyloid proteins deposited in organs differ and cause specific symptoms. The pathophysiological condition of amyloid protein accumulation in the heart is called cardiac amyloidosis. Typical precursor proteins that give rise to cardiac amyloidosis are immunoglobulin light chains and transthyretin, termed the AL and ATTR types, respectively. Cardiac amyloidosis has a poor prognosis with many cases of sudden death due to pump failure and fatal arrhythmias, especially in AL, where the frequency of fatal complications is reported to be high\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. In recent years, several new agents have been developed to improve the prognosis of the AL and ATTR types of cardiac amyloidosis. Daratumumab is a human IgG-κ monoclonal antibody that targets CD38, which is highly expressed on human plasma cells. Recent clinical studies showed that daratumumab combined with chemotherapy achieved better event-free survival and hematological responses in newly diagnosed systemic AL amyloidosis patients, including cardiac amyloidosis\u003csup\u003e\u003cspan additionalcitationids=\"CR3\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e–\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. Tafamidis, developed as a pharmacological chaperone, improved the prognosis of patients with ATTR cardiac amyloidosis by stabilizing the tetrameric structure of transthyretin and inhibiting its tissue deposition\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. In current clinical practice, when amyloidosis is suspected, several biopsy samples are taken from patients, and if amyloid deposition is detected, the disease type is identified via immunostaining and a genetic diagnosis, which is very time-consuming, taking several weeks to several months. In this context where effective treatments are being developed, a more rapid diagnosis to identify the type of cardiac amyloidosis is needed.\u003c/p\u003e \u003cp\u003eRaman spectroscopy is a label-free optical measurement technique that assesses molecular structures by measuring the spectrum of scattered light induced by single-wavelength laser irradiation and detecting the wavenumber shift from irradiated light\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Each molecule has a unique “spectral fingerprint” depending on vibrating patterns, which may be identified by chemical bonds and three-dimensional structures. Raman spectroscopy has recently been used in analyses in biological and medical research\u003csup\u003e\u003cspan additionalcitationids=\"CR9\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e–\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. It is a non-destructive technique that does not depend on the state of samples, which enables its application to live organs. Raman spectroscopy is useful for detecting tumors\u003csup\u003e\u003cspan additionalcitationids=\"CR12\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e–\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e, myocardial infarction\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e, skin inflammation\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e and amyloid-β protein in Alzheimer’s disease\u003csup\u003e\u003cspan additionalcitationids=\"CR17\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e–\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. Raman spectroscopy is also increasingly used as a surgery-assisting tool\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. In recent years, many attempts have been made to improve diagnostic accuracy by using artificial intelligence (AI) or machine learning to analyze spectra obtained by Raman spectroscopy\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. However, living organs comprise a wide variety of molecules, each of which produces scattered light with multiple Raman shifts, and when these overlap, it becomes difficult to identify single molecules. On the other hand, in pathologies such as amyloidosis, a single substance aggregates densely in tissue and, thus, it is easier to detect. We previously examined clinical biopsy specimens from patients with amyloidosis and reported that optical mapping based on Raman spectra derived from the β-sheet structure, which is abundant in amyloid protein, detected amyloid-deposition sites\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Our findings demonstrated the potential of a Raman spectroscopic analysis to more rapidly diagnose amyloid deposition in tissues. However, it remains unclear whether it has the ability to detect differences in disease types. Therefore, with the aim of rapidly diagnosing the disease type of cardiac amyloidosis, we herein analyzed spectra in more detail to establish whether a Raman spectral analysis discriminates between the AL and ATTR types of cardiac amyloidosis.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003ePatient background\u003c/h2\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows the summarized data of patients enrolled in the present study. Between 2018 and 2024 we treated 4 AL and 4 ATTR cardiac amyloidosis patients. Although the small number of patients who participated during the current study period makes it difficult to examine the significance of differences, the followings were observed. 1) Patients with ATTR amyloidosis were slightly older than those with AL amyloidosis. 2) The NYHA functional classification, which represents the clinical severity of heart failure, was higher in AL amyloidosis than in ATTR amyloidosis, indicating that AL amyloidosis resulted in more severe heart failure. 3) The thicknesses of interventricular septum and left ventricular posterior wall in echocardiography, which indicate myocardial hypertrophy, were slightly wider in ATTR, suggesting that cardiac hypertrophy was more intense in ATTR cardiac amyloidosis. 4) The serum level of brain natriuretic peptide, a biomarker of heart failure, was slightly higher in AL amyloidosis, also suggesting that heart failure was more severe in the AL type of cardiac amyloidosis than in the ATTR type. Such patient background was well consistent with previous reports of sudden death in AL and ATTR types of cardiac amyloidosis\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePatient data on AL and ATTR cardiac amyloidosis.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAL (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;4)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eATTR (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;4)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e64.0 (49\u0026ndash;74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e76.0 (65\u0026ndash;88)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale (Female)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNumber of\u003c/p\u003e \u003cp\u003eNYHA class III or IV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBNP [pg/mL]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1992.3 (65.5\u0026ndash;5679.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e231.4 (99.1\u0026ndash;330.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLVDd [mm]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43.0 (33\u0026ndash;54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e48.0 (46\u0026ndash;50)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLVEF [%]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e56.8 (48\u0026ndash;66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e56.3 (45\u0026ndash;62)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e%FS [%]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e28.0 (18\u0026ndash;49)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27.5 (23\u0026ndash;38)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIVST [mm]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12.1 (8.3\u0026ndash;14.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12.7 (8.6\u0026ndash;15.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLVPWT [mm]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11.9 (7.8\u0026ndash;14.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12.5 (8.8\u0026ndash;14.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLAD [mm]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e45.0 (35\u0026ndash;50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e46.8 (37\u0026ndash;51)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"3\"\u003eNYHA class: New York Heart Association functional classification, BNP: brain natriuretic peptide, LVDd: diastolic left ventricular diameter, LVEF: left ventricular ejection fraction, %FS: fractional shortening, IVST: thickness of the interventricular septum, LVPWT: thickness of the left ventricular posterior wall, LAD: left atrial diameter.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eRaman imaging and Raman spectra of AL and ATTR cardiac amyloidosis\u003c/h3\u003e\n\u003cp\u003eRepresentative transmitted light microscopy images (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA) and polarized light microscopy images (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB) of Congo-Red-stained specimens as well as transmitted light microscopic images of unstained specimens (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC), Raman images (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD) and Raman spectra (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE) obtained from adjacent unstained specimens are shown. Similar to our previous findings\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e, amyloid-deposition areas that stain red with Congo-Red and exhibited apple green birefringence in polarized light microscopy were shown in white in the Raman image, indicating that Raman intensity at 1680 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e was very strong. Additionally, the peak at 1680 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e, which was assigned to an amide I bond, was clearly visible at the amyloid deposition sites of AL and ATTR cardiac amyloidosis. This was consistent with our previous findings\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eDetection of amyloid-deposition regions in heart tissue based on principal component analysis (PCA) of Raman spectra\u003c/b\u003e \u003c/p\u003e \u003cp\u003eTo assess differences more objectively in Raman spectra between normal and amyloid-deposition areas, we performed PCA of total Raman spectral data to create scatter plots of two different principal components (PCs). Figure\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA shows a scatterplot based on PC1 and PC3. Although there was some overlap, plots of the amyloid deposition areas (closed dots) were more likely to be clustered in the dotted box, while those of normal tissue areas (open dots) were more likely to be dispersed around them. To confirm whether the results of PCA of Raman spectra discriminated between amyloid-deposition and non-deposition regions, we created a receiver operating characteristic (ROC) curve based on PC3 obtained by PCA. The area under the curve (AUC), sensitivity, and specificity were 0.78, 0.84, and 0.74, respectively.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe also tested the ability to identify amyloid deposition sites based on Raman spectra separately for AL and ATTR cardiac amyloidosis. Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eA is a scatter plot based on the results of PCA of Raman spectroscopy of AL cardiac amyloidosis. Although there was some overlap, the distribution of the plots of amyloid deposition area (orange dots) and normal area (open dots) appeared to differ. The ROC curve based on PCA results showed AUC of 0.69, sensitivity of 0.87, and specificity of 0.59 (Fig. \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003eA). Figure \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eA is a scatterplot based on the results of PCA of Raman spectroscopy of ATTR cardiac amyloidosis. Although there was some overlap, the distribution of plots of the amyloid deposition area (green dots) and normal area (open dots) appeared to differ. The ROC curve based on PCA results showed that AUC, sensitivity, and specificity were 0.77, 0.75, and 0.88, respectively (Fig. \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003eB). These results suggest the potential to detect amyloid-deposition sites with high accuracy based on the PCA of Raman spectroscopy.\u003c/p\u003e \u003cp\u003e \u003cb\u003eDiscrimination of AL and ATTR cardiac amyloidosis based on principal component analysis of Raman spectra.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eWe performed PCA using only data obtained from amyloid deposition regions in both AL and ATTR cardiac amyloidosis to investigate whether it is possible to distinguish between the AL and ATTR types. Figure\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA shows a scatterplot of PC1 and PC6 based on the PCA of data limited to amyloid deposition areas. Although there was a slight overlap, AL (orange dots) and ATTR (green dots) were separated by positive and negative values of PC6, respectively. Figure\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB shows the ROC curve generated to confirm whether AL and ATTR may be discriminated based on the results of the PCA of Raman spectra obtained at amyloidosis deposition areas. AUC, sensitivity, and specificity were 0.78, 0.80, and 0.71, respectively.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eIn Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e, the average spectral waveforms of the amyloid deposition regions in AL and ATTR cardiac amyloidosis were compared side by side with the loading waveform of PC6 in the wavenumber range of 1250\u0026ndash;1800 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e. A difference was observed between the Raman spectral intensities of AL and ATTR in the range of 1520\u0026ndash;1540 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e (solid box). Multiple peak-fitting in the range of 1500\u0026ndash;1550 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e revealed a typical peak at 1537 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e in the spectrum of AL, but not ATTR. The loading wave of PC6 obtained by the PCA of Raman spectra in amyloid-deposition regions shows an upward broad peak at 1537 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e (dotted box). The spectral difference in 1520\u0026ndash;1540 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e was considered to contribute to the highly accurate discrimination of AL and ATTR based on PC6.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe then investigated whether the difference in the Raman peak at 1537 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e in amyloid-deposition regions in AL and ATTR was due to variations in the amino acid content of their precursor proteins. Figure\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e shows the three-dimensional structure of amyloid fibrils consisting of immunoglobulin light chains (lambda type) with the IGLV1-44 mutation, which is one of the most common mutations observed in AL amyloidosis\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e, and wild-type transthyretin\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. The amino acid sequences of both precursor proteins are shown in Figure S3, and the content of amino acids in both proteins are also summarized in Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e in supplementary data. According to previous studies\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e, among the 20 amino acids that make up the human body, those with peaks around the wavenumber of 1538 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e were glycine (1515 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e), asparagine (1541 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e), isoleucine (1547 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e), leucine (1514 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e), proline (1548 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e), and tryptophan (1559 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e). The total numbers of the six amino acids in the amyloid-forming portion of immunoglobulin light chains and transthyretin were 31 (34%) and 29 (26%), respectively. Their content differed by 8%. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e, the content of six amino acids colored red differed and also appeared to be denser and in closer proximity in immunoglobulin light chains than in transthyretin. The different amino acid sequences of the precursor proteins may be responsible for the differences observed in Raman spectra in amyloid-deposition areas of the two disease types of cardiac amyloidosis.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eWe successfully performed Raman spectroscopy on formalin-fixed paraffin-embedded sections of myocardial biopsy samples from patients with cardiac amyloidosis to detect sites of amyloid deposition in cardiac tissue. Furthermore, a detailed Raman spectral analysis using PCA revealed the potential to distinguish between the two most common forms of amyloid deposition in the heart, AL and ATTR.\u003c/p\u003e \u003cp\u003eSince Raman spectroscopy is an optical analysis that is non-destructive and does not require special sample preparation, it has been considerd to be useful for biological applications, especially as an aid in medical diagnosis, and much research has been conducted. However, spectra derived from living organs contain a large amount of foreign information and are very difficult to analyze. Recent developments in AI and machine learning have provided one solution to this problem\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. PCA is a statistical analysis method that aggregates data with many variables to create PCs to reduce the dimensionality of the data and facilitate comparison between data, and is a method frequently used in analysis of Raman spectral data as a type of unsupervised machine learning. In this study, we verified whether it is possible to detect amyloid deposition or discriminate between AL and ATTR based on the PCs obtained by PCA, and showed that the ROC curve had good diagnostic ability with an AUC of approximately 0.8. In the future, it is expected that more clinical data will be collected and supervised machine learning will be applied to enable even higher accuracy in diagnosis.\u003c/p\u003e \u003cp\u003eThe problem still remains that diagnosis by AI and machine learning obscures the basis for the diagnosis, and explainable AI (XAI) would be one solution for this problem. Recently, XAI has been applied especially in the field of diagnostic imaging, and there is an increasing demand for XAI to show the basis of diagnosis\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. However, XAI is not yet easy to introduce due to the complexity of the program, development costs, and other reasons. In such situation, it is also very important to add pathological or material science considerations to the differences in analysis of Raman spectra in order to obtain diagnostic certainty on a rational basis. We carefully examined the PCs obtained by PCA and the raw spectral data and found that the peak at 1680 cm\u003csup\u003e− 1\u003c/sup\u003e and 1537 cm\u003csup\u003e− 1\u003c/sup\u003e may be useful for detecting amyloid accumulation and discriminating between AL and ATTR, respectively. Furthermore, we tried to obtain theoretical support for the diagnosis based on these peaks by considering what molecular structure each peak is derived from.\u003c/p\u003e \u003cp\u003eWe previously reported that the Raman peak assigned to the Amid-I bond near 1680 cm\u003csup\u003e− 1\u003c/sup\u003e was useful for detecting amyloid deposition in the tissues of various organs, including the heart, in patients with AL amyloidosis\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Since a Raman spectroscopic analysis of immunoglobulins revealed a peak for the Amid-I bond\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e, we considered the peak for the Amid-I bond to be specific to AL amyloidosis. However, in the present study, the Raman peak at 1680 cm\u003csup\u003e− 1\u003c/sup\u003e was still visible in amyloid-deposition regions, even in cardiac biopsy samples from ATTR amyloidosis patients. Therefore, we concluded that the 1680 cm\u003csup\u003e− 1\u003c/sup\u003e peak was derived from the β-sheet structure of amyloid protein. Amyloid protein, which is deposited in tissues in amyloidosis, is a general term for a single protein that transforms into a β-sheet structure. The precursor proteins and peptides of amyloid proteins differ depending on the disease, with immunoglobulin light chains aggregating in AL and transthyretin aggregating in ATTR. Even though the precursor proteins differ, the β-sheet structure that is common to amyloid protein aggregates in a narrow region\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e, and the Raman peak at 1680 cm\u003csup\u003e− 1\u003c/sup\u003e assigned to the β-sheet structure of the Amid-I bond is considered to be useful for detecting amyloid deposition areas with high sensitivity\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn the present study, we analyzed the Raman spectra of amyloid deposition sites in detail and showed the possibility that differences in precursor proteins were reflected in Raman spectra. In a comparison of Raman spectra restricted to the amyloid deposition area, we found an apparent difference in Raman intensity between the AL and ATTR types of cardiac amyloidosis at the 1520–1540 cm\u003csup\u003e− 1\u003c/sup\u003e wavenumber region. A detailed analysis by peak fitting also revealed a characteristic peak at 1537 cm\u003csup\u003e− 1\u003c/sup\u003e in the AL type of cardiac amyloidosis, but not in the ATTR type. This difference in Raman spectra at 1537 cm\u003csup\u003e− 1\u003c/sup\u003e may have been due to different amino acid sequences in the precursor proteins of AL and ATTR and, thus, we compared the amino acid sequences of the amyloid fibril-forming parts of immunoglobulin light chains and transthyretin. We found that the content of amino acids, which have a Raman peak near 1537 cm\u003csup\u003e− 1 26,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e, was nearly 10% higher in immunoglobulin light chains than in transthyretin. Since the intensity of the Raman spectra of each amino acid must also be considered and spectra may change due to peptide binding, it is still difficult to draw conclusions based on amino acid contents alone. Although studies comparing the Raman spectra of amino acids with those of peptides and proteins have been conducted since the development of Raman spectroscopy, differences in amino acid sequences and complex three-dimensional structures have made it difficult to predict changes in Raman spectra\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e. Attempts have been made to diagnose diseases using amino acids and peptides with characteristic spectra, such as aromatic amino acids and protonated phosphate groups, as indicators, but these have not been put to practical use\u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. It has been reported that by combining machine learning models, which have been remarkably developed in recent years, with classical force-field molecular dynamics, it has become possible to construct a model that predicts the Raman spectra of peptides from the Raman spectra of amino acids\u003csup\u003e\u003cspan additionalcitationids=\"CR38\" citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e–\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e. If more data are accumulated and such models are established in the future, it may be possible to predict variations in Raman spectra due to differences in precursor proteins in advance, and also to construct a model that discriminates disease types based on these predicted Raman spectra.\u003c/p\u003e \u003cp\u003eThe prognosis of patients with systemic amyloidosis is negatively impacted by cardiac amyloidosis, which causes amyloid deposition in the heart. Even in non-fatal cases, cardiac amyloidosis is associated with repeated heart attacks and significantly impairs the quality of life of patients. Although the prognosis of cardiac amyloidosis has improved in recent years with the development of new therapies\u003csup\u003e\u003cspan additionalcitationids=\"CR3 CR4 CR5\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e–\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e, a prompt diagnosis is essential for the initiation of treatment as soon as possible in order to maximize therapeutic effects. Moreover, since treatment methods differ between AL and ATTR amyloidosis, it is important to rapidly diagnose not only the presence or absence of amyloid deposition, but also the disease type. Until now, research on the diagnosis of amyloidosis by Raman spectroscopy has mainly focused on the detection of amyloid protein. Kim et al. reported that Raman spectroscopy could not only identify the site of amyloid deposition in renal amyloidosis but also discriminate between amyloid A (AA) and AL types of amyloidosis\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. This was one of the few studies to demonstrate the applicability of Raman spectroscopy to the classification of disease types in amyloidosis. To the best of our knowledge, the present study is the first to classify of the disease types of cardiac amyloidosis using Raman spectroscopy and demonstrate its potential. In the future, if it becomes possible to detect amyloid deposition based on the peak derived from the Amid-I bond at 1680 cm\u003csup\u003e− 1\u003c/sup\u003e and further classify the disease type based on the peak around 1537 cm\u003csup\u003e− 1\u003c/sup\u003e using a detailed spectral analysis of the same region, the diagnosis of cardiac amyloidosis may be expedited. Since Raman spectroscopy may analyze unstained specimens, a rapid diagnosis may be possible after a biopsy sample is taken, which will enable the early initiation of treatment.\u003c/p\u003e \u003cp\u003eThere were several limitations that need to be addressed. The number of patients included was very small, 4 each for AL and ATTR, and it remains unclear whether a similar spectrum useful for diagnosis could be obtained when the patient number of cases increases. Another form of systemic amyloidosis that may be complicated by cardiac amyloidosis is AA amyloidosis due to chronic inflammation. AA amyloidosis was not involved in the present study. Furthermore, there are multiple forms of AL amyloidosis, such as the lambda and kappa types of immunoglobulin light chains, and ATTR amyloidosis, including the hereditary and wild types. Although it is necessary to diagnose these types in order to develop a precise treatment strategy for each patient, the number of cases in this study was small and we have not yet reached that level of classification. Further spectral analyses and the accumulation of more cases subjected to a Raman spectroscopic analysis are necessary in the future.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003e\u003cb\u003eCollection of clinical biopsy samples\u003c/b\u003e\u003c/p\u003e\u003cp\u003eAll clinical studies were approved by the Institutional Review Board of Tokushima University (approval number: 3507-3). All methods were performed in accordance with the guidelines and regulations of Tokushima University, which was created on the basis of Declaration of Helsinki. Written informed consent was obtained from patients for the collection of biopsy samples for diagnosis and the use of some specimens for research purposes. The background data of patients enrolled in the present study are summarized in Table\u0026nbsp;1. Cardiac biopsy samples were fixed in formalin and embedded in paraffin, and two or more serial sections (thickness of 3 \u0026micro;m) were prepared using a microtome. One of the serial sections was stained with Congo Red for polarized light microscopy and the adjacent sections were left unstained for Raman spectroscopy.\u003c/p\u003e\u003cp\u003e\u003cb\u003eRaman microscopy and image construction\u003c/b\u003e\u003c/p\u003e\u003cp\u003ePrior to Raman microscopy, Congo Red stained specimens were observed by polarized light microscopy (OPTIPHOT2-POL, Nikon Co.) to identify the area with apple green birefringence, which was presumed to be the amyloid deposition site. Based on the findings of polarized light microscopy, we identified the location for Raman spectroscopy as the region of interest.\u003c/p\u003e\u003cp\u003eConsecutive unstained specimens were observed by Raman spectroscopy (Raman11, Nanophoton Corporation, Osaka, Japan) as previously described\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. The laser (central wavelength 532 nm, power 10\u0026ndash;12 mW) was illuminated through an objective lens (LUCPLAN, x20, N.A. 0.45, Olympus Co., Tokyo, Japan) and sample observations were simultaneously performed through the same objective lens. Measurements were conducted in the x-y line scan mode. Briefly, the laser was expanded in the x-axis direction to illuminate the sample in a linear manner (exposure time 600 s), and the resulting spectral data were simultaneously acquired by 400 CCD array and scanned repeatedly in the y-axis direction 70\u0026ndash;80 times. The diffraction grating and central wavenumber were 1200 lines/mm and 1850 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e, respectively. The measurement range and wavenumber resolution were approximately 1350\u0026ndash;2350 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e and 0.9 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e, respectively. A final spatial resolution of 1 \u0026micro;m was achieved, and data including Raman spectra were acquired for each pixel. A Raman image was constructed based on spectral information of each pixel. The ratio of Raman scattering intensities in the wavenumber range of 1665\u0026ndash;1680 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e to that in the wavenumber range of 1580\u0026ndash;1600 cm\u003csup\u003e\u0026minus;\u0026thinsp;1\u003c/sup\u003e was calculated, and the image was displayed with a pseudo-color gradient of black, magenta, cyan, and white from the lowest to highest ratio.\u003c/p\u003e\u003cp\u003e\u003cb\u003ePCA and creation of ROC curves\u003c/b\u003e\u003c/p\u003e\u003cp\u003eThe Raman spectra of normal and amyloid-deposition areas were extracted, and numerical data were subjected to PCA. A two-dimensional scatter plot analysis was performed based on extracted PCs. ROC curves were constructed to evaluate sensitivity and specificity for predicting amyloid deposition or the discrimination of disease types based on PCA. PCA of the spectral data and a ROC curve analysis were performed using Python ver.3.10.9\u003csup\u003e41\u003c/sup\u003e. A more detailed spectral analysis within the wavenumber range of interest was conducted using multiple peak-fitting method by Igor Pro ver.9.0.5.1 (WaveMetrics)\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003e\u003cb\u003eAmino acid sequence analysis\u003c/b\u003e\u003c/p\u003e\u003cp\u003eTo investigate whether differences in the amino acid sequences of precursor proteins represent a difference in Raman spectra, we constructed the 3-dimensional structures of amyloid proteins of immunoglobulin light chains and transthyretin based on previous studies\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e, and colored several target amino acids in red using UCSF Chimera software\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eConflict of interest\u003c/h2\u003e \u003cp\u003eThe authors declare that there is no conflict of interest.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding sources\u003c/h2\u003e \u003cp\u003eThis work was supported by the JSPS KAKENHI (grant number JP19H04443 [H.T.], JP20K08712 [H.M.], and JP22K04713 [S.Y.]), Health Laubour Science Research Grant (grant number 23FC1035 [H.M.]), Japanese Society of Hematology Research Grants (20289 and 24155), and Japan Leukaemia Research Fund [H.M.].\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eM.Y.: Investigation, formal analysis, software programming, writing-original draft. S.Y.: Conceptualization, investigation, software programming, formal analysis, writing-review \u0026amp; editing draft, funding. H.T.: Conceptualization, investigation, formal analysis, writing-review \u0026amp; editing draft, funding. T.H.: Investigation, formal analysis. Y.M.: Collection of clinical samples \u0026amp; data, review \u0026amp; editing the draft. R.S.: Collection of clinical samples \u0026amp; data, review \u0026amp; editing the draft. M.O.: Collection of clinical samples \u0026amp; data, review \u0026amp; editing the draft. K.S.: Collection of clinical samples \u0026amp; data, review \u0026amp; editing the draft. T.H.: Collection of clinical samples \u0026amp; data, review \u0026amp; editing the draft. S.F.: Collection of clinical samples \u0026amp; data, review \u0026amp; editing the draft. S.N.: Collection of clinical samples \u0026amp; data. Y.B.: Review \u0026amp; editing the draft. K.T.: Preparation of specimens, review \u0026amp; editing the draft. I.E.: Review \u0026amp; editing the draft. M.A.: Review \u0026amp; editing the draft. K.M.: Review \u0026amp; editing the draft. H.M.: Conceptualization, supervision, collection of clinical samples \u0026amp; data, investigation, formal analysis, writing-review \u0026amp; editing draft, funding.\u003c/p\u003e\u003ch2\u003eAcknowledgement\u003c/h2\u003e\u003cp\u003eThe authors thank Prof. Takaaki Yano (Institute of Post-LED Photonics, Tokushima University, Tokushima, Japan) for all his help with instrumentation. The authors also thank Nanophoton, a Bruker Company, for their support in data acquisition. The authors appreciate Yuka Kanno (Division of Pathology, Tokushima University Hospital, Tokushima, Japan) for her technical assistance. Molecular graphics and analyses were performed with UCSF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311. We would like to thank Medical English Service for their assistance with English language editing.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eAll data supporting the findings of this study are available within this draft manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003ede Frutos, F. et al. Incidence and predictors of sudden death in patients with cardiac amyloidosis. \u003cem\u003eAmyloid\u003c/em\u003e \u003cb\u003e31\u003c/b\u003e, 334\u0026ndash;338. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/13506129.2024.2414295\u003c/span\u003e\u003cspan address=\"10.1080/13506129.2024.2414295\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKastritis, E. et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. \u003cem\u003eN. Engl. J. Med.\u003c/em\u003e \u003cb\u003e385\u003c/b\u003e, 46\u0026ndash;58. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa2028631\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa2028631\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOubari, S. et al. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. \u003cem\u003eHaematologica\u003c/em\u003e \u003cb\u003e109\u003c/b\u003e, 220\u0026ndash;230. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3324/haematol.2023.283325\u003c/span\u003e\u003cspan address=\"10.3324/haematol.2023.283325\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZanwar, S. et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. \u003cem\u003eLeukemia\u003c/em\u003e \u003cb\u003e38\u003c/b\u003e, 1423\u0026ndash;1426. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41375-024-02243-5\u003c/span\u003e\u003cspan address=\"10.1038/s41375-024-02243-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaurer, M. S. et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. \u003cem\u003eN. Engl. J. Med.\u003c/em\u003e \u003cb\u003e379\u003c/b\u003e, 1007\u0026ndash;1016. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa1805689\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa1805689\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eaus dem Siepen, F. et al. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval. \u003cem\u003eAmyloid\u003c/em\u003e 31, 226\u0026ndash;231, (2024). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/13506129.2024.2376202\u003c/span\u003e\u003cspan address=\"10.1080/13506129.2024.2376202\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRaman, C. V. \u0026amp; Krishnan, K. S. The Negative Absorption of Radiation. \u003cem\u003eNature\u003c/em\u003e \u003cb\u003e122\u003c/b\u003e, 12\u0026ndash;13. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/122012b0\u003c/span\u003e\u003cspan address=\"10.1038/122012b0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1928).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eButler, H. J. et al. Using Raman spectroscopy to characterize biological materials. \u003cem\u003eNat. Protoc.\u003c/em\u003e \u003cb\u003e11\u003c/b\u003e, 664\u0026ndash;687. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nprot.2016.036\u003c/span\u003e\u003cspan address=\"10.1038/nprot.2016.036\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDurrant, B., Trappett, M., Shipp, D. \u0026amp; Notingher, I. Recent developments in spontaneous Raman imaging of living biological cells. \u003cem\u003eCurr. Opin. Chem. Biol.\u003c/em\u003e \u003cb\u003e51\u003c/b\u003e, 138\u0026ndash;145. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cbpa.2019.06.004\u003c/span\u003e\u003cspan address=\"10.1016/j.cbpa.2019.06.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMinamikawa, T. et al. Molecular imaging analysis of microvesicular and macrovesicular lipid droplets in non-alcoholic fatty liver disease by Raman microscopy. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e10\u003c/b\u003e, 18548. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-020-75604-6\u003c/span\u003e\u003cspan address=\"10.1038/s41598-020-75604-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKong, K. et al. Diagnosis of tumors during tissue-conserving surgery with integrated autofluorescence and Raman scattering microscopy. \u003cem\u003eProc. Natl. Acad. Sci. U.S.A.\u003c/em\u003e \u003cb\u003e110\u003c/b\u003e, 15189\u0026ndash;15194. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1073/pnas.1311289110\u003c/span\u003e\u003cspan address=\"10.1073/pnas.1311289110\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong, D. et al. Raman spectroscopy combined with multivariate analysis to study the biochemical mechanism of lung cancer microwave ablation. \u003cem\u003eBiomed. Opt. Express\u003c/em\u003e. \u003cb\u003e11\u003c/b\u003e, 1061\u0026ndash;1072. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1364/BOE.383869\u003c/span\u003e\u003cspan address=\"10.1364/BOE.383869\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEmber, K. et al. In situ brain tumor detection using a Raman spectroscopy system\u0026mdash;results of a multicenter study. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e14\u003c/b\u003e, 13309. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-024-62543-9\u003c/span\u003e\u003cspan address=\"10.1038/s41598-024-62543-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYamamoto, T. et al. Label-free Evaluation of Myocardial Infarct in Surgically Excised Ventricular Myocardium by Raman Spectroscopy. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e8\u003c/b\u003e, 14671. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-018-33025-6\u003c/span\u003e\u003cspan address=\"10.1038/s41598-018-33025-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKanemura, Y. et al. Assessment of skin inflammation using near-infrared Raman spectroscopy combined with artificial intelligence analysis in an animal model. \u003cem\u003eAnalyst\u003c/em\u003e \u003cb\u003e147\u003c/b\u003e, 2843\u0026ndash;2850. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1039/d2an00193d\u003c/span\u003e\u003cspan address=\"10.1039/d2an00193d\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePopova, L. A., Kodali, R., Wetzel, R. \u0026amp; Lednev, I. K. Structural variations in the cross-beta core of amyloid beta fibrils revealed by deep UV resonance Raman spectroscopy. \u003cem\u003eJ. Am. Chem. Soc.\u003c/em\u003e \u003cb\u003e132\u003c/b\u003e, 6324\u0026ndash;6328. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/ja909074j\u003c/span\u003e\u003cspan address=\"10.1021/ja909074j\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShashilov, V. et al. Dissecting structure of prion amyloid fibrils by hydrogen-deuterium exchange ultraviolet Raman spectroscopy. \u003cem\u003eJ. Phys. Chem. B\u003c/em\u003e. \u003cb\u003e116\u003c/b\u003e, 7926\u0026ndash;7930. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/jp2122455\u003c/span\u003e\u003cspan address=\"10.1021/jp2122455\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLochocki, B. et al. Multimodal, label-free fluorescence and Raman imaging of amyloid deposits in snap-frozen Alzheimer\u0026rsquo;s disease human brain tissue. \u003cem\u003eCommun. Biology\u003c/em\u003e. \u003cb\u003e4\u003c/b\u003e, 474. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s42003-021-01981-x\u003c/span\u003e\u003cspan address=\"10.1038/s42003-021-01981-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHanna, K. et al. Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects. \u003cem\u003eBr. J. Cancer\u003c/em\u003e. \u003cb\u003e126\u003c/b\u003e, 1125\u0026ndash;1139. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41416-021-01659-5\u003c/span\u003e\u003cspan address=\"10.1038/s41416-021-01659-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, Y. et al. Raman spectroscopy: A prospective intraoperative visualization technique for gliomas. \u003cem\u003eFront. Oncol.\u003c/em\u003e \u003cb\u003e12\u003c/b\u003e, 1086643. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fonc.2022.1086643\u003c/span\u003e\u003cspan address=\"10.3389/fonc.2022.1086643\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhu, G. et al. Rapid diagnosis of membranous nephropathy based on kidney tissue Raman spectroscopy and deep learning. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e15\u003c/b\u003e, 13038. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-025-97351-2\u003c/span\u003e\u003cspan address=\"10.1038/s41598-025-97351-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2025).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLazzini, G. et al. Raman spectroscopy based diagnosis of pancreatic ductal adenocarcinoma. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e15\u003c/b\u003e, 13240. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-025-98122-9\u003c/span\u003e\u003cspan address=\"10.1038/s41598-025-98122-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2025).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYanagiya, S. et al. Raman microspectroscopy for label-free diagnosis of amyloid light-chain amyloidosis in various organs. \u003cem\u003eJ. Raman Spectrosc.\u003c/em\u003e \u003cb\u003e55\u003c/b\u003e, 753\u0026ndash;760. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/jrs.6665\u003c/span\u003e\u003cspan address=\"10.1002/jrs.6665\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRadamaker, L. et al. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. \u003cem\u003eNat. Commun.\u003c/em\u003e \u003cb\u003e10\u003c/b\u003e, 1103. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41467-019-09032-0\u003c/span\u003e\u003cspan address=\"10.1038/s41467-019-09032-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchmidt, M. et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. \u003cem\u003eNat. Commun.\u003c/em\u003e \u003cb\u003e10\u003c/b\u003e, 5008. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41467-019-13038-z\u003c/span\u003e\u003cspan address=\"10.1038/s41467-019-13038-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhu, G., Zhu, X., Fan, Q. \u0026amp; Wan, X. Raman spectra of amino acids and their aqueous solutions. \u003cem\u003eSpectrochim. Acta Part A Mol. Biomol. Spectrosc.\u003c/em\u003e \u003cb\u003e78\u003c/b\u003e, 1187\u0026ndash;1195. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.saa.2010.12.079\u003c/span\u003e\u003cspan address=\"10.1016/j.saa.2010.12.079\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWen, C. I., Yu, C. N., Thirumalaivasan, N. \u0026amp; Hiramatsu, H. 532-nm-excited hyper-Raman spectroscopy of amino acids. \u003cem\u003eJ. Raman Spectrosc.\u003c/em\u003e \u003cb\u003e52\u003c/b\u003e, 641\u0026ndash;654. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/jrs.6039\u003c/span\u003e\u003cspan address=\"10.1002/jrs.6039\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan der Velden, B. H. M., Kuijf, H. J., Gilhuijs, K. G. A. \u0026amp; Viergever, M. A. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. \u003cem\u003eMed. Image Anal.\u003c/em\u003e \u003cb\u003e79\u003c/b\u003e, 102470. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.media.2022.102470\u003c/span\u003e\u003cspan address=\"10.1016/j.media.2022.102470\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSalih, A. et al. Explainable Artificial Intelligence and Cardiac Imaging: Toward More Interpretable Models. \u003cem\u003eCirc. Cardiovasc. Imaging\u003c/em\u003e. \u003cb\u003e16\u003c/b\u003e, e014519. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/circimaging.122.014519\u003c/span\u003e\u003cspan address=\"10.1161/circimaging.122.014519\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOta, C., Noguchi, S., Nagatoishi, S. \u0026amp; Tsumoto, K. Assessment of the Protein-Protein Interactions in a Highly Concentrated Antibody Solution by Using Raman Spectroscopy. \u003cem\u003ePharm. Res.\u003c/em\u003e \u003cb\u003e33\u003c/b\u003e, 956\u0026ndash;969. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11095-015-1842-8\u003c/span\u003e\u003cspan address=\"10.1007/s11095-015-1842-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEttah, I. \u0026amp; Ashton, L. Engaging with Raman Spectroscopy to Investigate Antibody Aggregation. \u003cem\u003eAntibodies (Basel)\u003c/em\u003e. \u003cb\u003e7\u003c/b\u003e \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/antib7030024\u003c/span\u003e\u003cspan address=\"10.3390/antib7030024\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePelton, J. T. \u0026amp; McLean, L. R. Spectroscopic methods for analysis of protein secondary structure. \u003cem\u003eAnal. Biochem.\u003c/em\u003e \u003cb\u003e277\u003c/b\u003e, 167\u0026ndash;176. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1006/abio.1999.4320\u003c/span\u003e\u003cspan address=\"10.1006/abio.1999.4320\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKurouski, D., Van Duyne, R. P. \u0026amp; Lednev, I. K. Exploring the structure and formation mechanism of amyloid fibrils by Raman spectroscopy: a review. \u003cem\u003eAnalyst\u003c/em\u003e \u003cb\u003e140\u003c/b\u003e, 4967\u0026ndash;4980. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1039/c5an00342c\u003c/span\u003e\u003cspan address=\"10.1039/c5an00342c\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGarfinkel, D. Raman Spectra of Amino Acids and Related Compounds. XII. Various Amino Acids Derived from Proteins and Creatine1,2. \u003cem\u003eJ. Am. Chem. Soc.\u003c/em\u003e \u003cb\u003e80\u003c/b\u003e, 3827\u0026ndash;3831. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/ja01548a005\u003c/span\u003e\u003cspan address=\"10.1021/ja01548a005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1958).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXie, Y., Jiang, Y. \u0026amp; Ben-Amotz, D. Detection of amino acid and peptide phosphate protonation using Raman spectroscopy. \u003cem\u003eAnal. Biochem.\u003c/em\u003e \u003cb\u003e343\u003c/b\u003e, 223\u0026ndash;230. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ab.2005.05.038\u003c/span\u003e\u003cspan address=\"10.1016/j.ab.2005.05.038\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eContorno, S., Darienzo, R. E. \u0026amp; Tannenbaum, R. Evaluation of aromatic amino acids as potential biomarkers in breast cancer by Raman spectroscopy analysis. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e11\u003c/b\u003e, 1698. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-021-81296-3\u003c/span\u003e\u003cspan address=\"10.1038/s41598-021-81296-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePaidi, S. K. et al. Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy. \u003cem\u003eCancer Res.\u003c/em\u003e \u003cb\u003e81\u003c/b\u003e, 5745\u0026ndash;5755. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1158/0008-5472.Can-21-1438\u003c/span\u003e\u003cspan address=\"10.1158/0008-5472.Can-21-1438\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHe, C. et al. Accurate Tumor Subtype Detection with Raman Spectroscopy via Variational Autoencoder and Machine Learning. \u003cem\u003eACS Omega\u003c/em\u003e. \u003cb\u003e7\u003c/b\u003e, 10458\u0026ndash;10468. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/acsomega.1c07263\u003c/span\u003e\u003cspan address=\"10.1021/acsomega.1c07263\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBerger, E., Niemel\u0026auml;, J., Lampela, O., Juffer, A. H. \u0026amp; Komsa, H. P. Raman Spectra of Amino Acids and Peptides from Machine Learning Polarizabilities. \u003cem\u003eJ. Chem. Inf. Model.\u003c/em\u003e \u003cb\u003e64\u003c/b\u003e, 4601\u0026ndash;4612. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/acs.jcim.4c00077\u003c/span\u003e\u003cspan address=\"10.1021/acs.jcim.4c00077\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim, J. H., Zhang, C., Sperati, C. J., Bagnasco, S. M. \u0026amp; Barman, I. Non-Perturbative Identification and Subtyping of Amyloidosis in Human Kidney Tissue with Raman Spectroscopy and Machine Learning. \u003cem\u003eBiosens. (Basel)\u003c/em\u003e. 13. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/bios13040466\u003c/span\u003e\u003cspan address=\"10.3390/bios13040466\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePython 3 Reference ManualCreateSpace, Scotts Valley, CA, (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePettersen, E. F. et al. UCSF Chimera\u0026ndash;a visualization system for exploratory research and analysis. \u003cem\u003eJ. Comput. Chem.\u003c/em\u003e \u003cb\u003e25\u003c/b\u003e, 1605\u0026ndash;1612. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/jcc.20084\u003c/span\u003e\u003cspan address=\"10.1002/jcc.20084\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2004).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Cardiac amyloidosis, Rapid diagnosis, Immunoglobulin light chains, Transthyretin, Raman spectroscopy","lastPublishedDoi":"10.21203/rs.3.rs-6795517/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6795517/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAlthough the prognosis of cardiac amyloidosis has improved with the development of therapies, the time required for disease typing remains a critical issue. We investigated the potential of Raman spectroscopy for the more rapid diagnosis and typing of cardiac amyloidosis.\u003cstrong\u003e \u003c/strong\u003eHeart biopsies were collected from patients with the AL (4) and ATTR (4) types of cardiac amyloidosis, and tissue sections were subjected to Raman microscopy. A principal component analysis (PCA) of spectral data was performed and receiver operating characteristic (ROC) curves were created to confirm the accuracy of discriminating between amyloid-deposition and non-deposition sites, and between AL and ATTR.\u003cstrong\u003e \u003c/strong\u003eThe steep peak at 1680 cm\u003csup\u003e-1\u003c/sup\u003e, reflecting the β-sheet structure, was useful for detecting the amyloid-deposition region. By restricting the spectral analysis to amyloid-deposition sites, AL and ATTR were discriminated by principal components with a characteristic broad peak at 1520–1540 cm\u003csup\u003e-1\u003c/sup\u003e, which was also observed in the Raman spectrum of AL, but not ATTR. The area under ROC curve discriminating AL and ATTR was 0.78.\u003cstrong\u003e \u003c/strong\u003ePCA of the Raman spectra of cardiac biopsies has the potential not only to detect amyloid-deposition sites in tissue but also to rapidly discriminate between the AL and ATTR types of cardiac amyloidosis.\u003c/p\u003e","manuscriptTitle":"Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-06-25 02:08:15","doi":"10.21203/rs.3.rs-6795517/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"e2c89ad9-f5dd-46c1-bb9f-dbe52b2de535","owner":[],"postedDate":"June 25th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":50264826,"name":"Biological sciences/Biological techniques"},{"id":50264827,"name":"Health sciences/Cardiology"},{"id":50264828,"name":"Physical sciences/Nanoscience and technology"}],"tags":[],"updatedAt":"2025-06-25T02:08:24+00:00","versionOfRecord":[],"versionCreatedAt":"2025-06-25 02:08:15","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6795517","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6795517","identity":"rs-6795517","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}